Parkinson's disease and Covid-19: The effect and use of telemedicine

Podlewska, Aleksandra; Wamelen, Daniel J. van

doi:10.1016/bs.irn.2022.04.002

Cited by 13 publications

(16 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Demographic characteristics are associated with patients’ uptake of digital therapeutics. Younger age [ 5 , 19 , 40 , 43 , 49 , 52 - 54 , 63 , 83 , 100 , 101 , 126 , 135 , 139 , 175 , 177 , 181 , 182 , 196 , 203 , 206 , 235 , 236 , 256 , 259 ], sex (male or female depending on the circumstances) [ 17 , 53 , 62 , 63 , 101 , 181 , 182 , 235 , 256 ], higher language skills [ 19 , 53 , 126 ], higher education level [ 5 , 17 , 43 , 49 , 54 , 62 , 63 , 83 , 100 , 101 , 107 , 135 , 175 , 177 , 181 , 182 ], higher health literacy [ 40 , 47 ], being employed [ 5 , 17 , 62 , 100 , 101 ], higher income level [ 17 , 40 , 52 , ...…”

Section: Resultsmentioning

confidence: 99%

“…Furthermore, cultural and social environments [ 49 , 62 , 71 , 82 , 86 , 115 , 135 , 142 , 159 , 193 , 195 , 235 ]; ethnic background [ 40 , 101 , 102 , 107 , 142 , 175 , 193 , 195 , 235 ]; being unhealthy or living with a disability [ 11 , 17 , 40 , 52 , 62 , 80 , 100 - 103 , 107 , 181 , 190 , 206 , 236 , 259 , 270 ]; patient-specific needs, attitudes, and habits [ 1 , 80 , 102 , 109 , 110 , 193 , 195 ]; distance to health services [ 152 , 171 , 185 , 236 ], risk of contracting a disease [ 165 ]; insurance status [ 175 , 270 ]; time since diagnosis [ 177 ]; and past health care experiences [ 217 ] can influence the uptake of digital therapeutics. The extent to which the target group can access the internet is an additional determinant of the uptake of digital therapeutics [ 17 , 19 , 52 , 53 , 62 , 63 , 76 , 77 <...…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Mapping Factors That Affect the Uptake of Digital Therapeutics Within Health Systems: Scoping Review

van Kessel,

Roman-Urrestarazu,

Anderson

et al. 2023

J Med Internet Res

View full text Add to dashboard Cite

Background Digital therapeutics are patient-facing digital health interventions that can significantly alter the health care landscape. Despite digital therapeutics being used to successfully treat a range of conditions, their uptake in health systems remains limited. Understanding the full spectrum of uptake factors is essential to identify ways in which policy makers and providers can facilitate the adoption of effective digital therapeutics within a health system, as well as the steps developers can take to assist in the deployment of products. Objective In this review, we aimed to map the most frequently discussed factors that determine the integration of digital therapeutics into health systems and practical use of digital therapeutics by patients and professionals. Methods A scoping review was conducted in MEDLINE, Web of Science, Cochrane Database of Systematic Reviews, and Google Scholar. Relevant data were extracted and synthesized using a thematic analysis. Results We identified 35,541 academic and 221 gray literature reports, with 244 (0.69%) included in the review, covering 35 countries. Overall, 85 factors that can impact the uptake of digital therapeutics were extracted and pooled into 5 categories: policy and system, patient characteristics, properties of digital therapeutics, characteristics of health professionals, and outcomes. The need for a regulatory framework for digital therapeutics was the most stated factor at the policy level. Demographic characteristics formed the most iterated patient-related factor, whereas digital literacy was considered the most important factor for health professionals. Among the properties of digital therapeutics, their interoperability across the broader health system was most emphasized. Finally, the ability to expand access to health care was the most frequently stated outcome measure. Conclusions The map of factors developed in this review offers a multistakeholder approach to recognizing the uptake factors of digital therapeutics in the health care pathway and provides an analytical tool for policy makers to assess their health system’s readiness for digital therapeutics.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Mapping Factors That Affect the Uptake of Digital Therapeutics Within Health Systems: Scoping Review

van Kessel,

Roman-Urrestarazu,

Anderson

et al. 2023

J Med Internet Res

View full text Add to dashboard Cite

show abstract

“…Indeed, it has been showed that patients presenting with ischemic stroke during the COVID-19 pandemic lockdown period had a reduced hospital care and higher hospitalization costs although the final outcome was unchanged compared to the period before lockdown ( 53 ). If the access at the emergency department is mandatory in the case of stroke, since PD is a chronic disease, telemedicine including remote delivery of treatment (e.g., ParkinDANCE program) proved to be successful in providing medical services to patients with PD ( 54 , 55 ).…”

Section: Prevalence and Outcome Of Covid-19 In Pd Patientsmentioning

confidence: 99%

COVID-19 and neurological disorders: what might connect Parkinson’s disease to SARS-CoV-2 infection

et al. 2023

View full text Add to dashboard Cite

SARS-CoV-2 infection leading to Coronavirus disease 19 (COVID-19) rapidly became a worldwide health emergency due to its elevated infecting capacity, morbidity, and mortality. Parkinson’s disease (PD) is the second most common neurodegenerative disorder and, nowadays the relationship between SARS-CoV-2 outbreak and PD reached a great interest. Apparently independent one from the other, both diseases share some pathogenetic and clinical features. The relationship between SARS-CoV-2 infection and PD is complex and it depends on the direction of the association that is which of the two diseases comes first. Some evidence suggests that SARS-CoV-2 infection might be a possible risk factor for PD wherein the exposure to SARS-CoV-2 increase the risk for PD. This perspective comes out from the increasing cases of parkinsonism following COVID-19 and also from the anatomical structures affected in both COVID-19 and early PD such as olfactory bulb and gastrointestinal tract resulting in the same symptoms such as hyposmia and constipation. Furthermore, there are many reported cases of patients who developed hypokinetic extrapyramidal syndrome following SARS-CoV-2 infection although these would resemble a post-encephalitic conditions and there are to date relevant data to support the hypothesis that SARS-CoV-2 infection is a risk factor for the development of PD. Future large, longitudinal and population-based studies are needed to better assess whether the risk of developing PD after COVID-19 exists given the short time span from the starting of pandemic. Indeed, this brief time-window does not allow the precise estimation of the incidence and prevalence of PD after pandemic when compared with pre-pandemic era. If the association between SARS-CoV-2 infection and PD pathogenesis is actually putative, on the other hand, vulnerable PD patients may have a greater risk to develop COVID-19 being also more prone to develop a more aggressive disease course. Furthermore, PD patients with PD showed a worsening of motor and non-motor symptoms during COVID-19 outbreak due to both infection and social restriction. As well, the worries related to the risk of being infected should not be neglected. Here we summarize the current knowledge emerging about the epidemiological, pathogenetic and clinical relationship between SARS-CoV-2 infection and PD.

show abstract

“…Delays in reaching recruitment targets represent a major challenge for clinical trials 1. A reduction in in-person clinic attendance with the introduction of new, remote care delivery models following the COVID-19 pandemic has further exacerbated this problem 2. Parkinson’s disease (PD) trials generally do not recruit representative populations, and therefore their results are not generalisable, which risks perpetuating healthcare inequalities 3.…”

Section: Introductionmentioning

confidence: 99%

“… 1 A reduction in in-person clinic attendance with the introduction of new, remote care delivery models following the COVID-19 pandemic has further exacerbated this problem. 2 Parkinson’s disease (PD) trials generally do not recruit representative populations, and therefore their results are not generalisable, which risks perpetuating healthcare inequalities. 3 Strategies to improve recruitment to trials have been evaluated, but other than telephone reminders and opt-out strategies, very few have been found to be effective.…”

Section: Introductionmentioning

confidence: 99%

Incorporating usability evaluation into iterative development of an online platform to support research participation in Parkinson’s disease: a mixed methods protocol

Chapman,

Zeissler,

Meinert

et al. 2023

BMJ Open

View full text Add to dashboard Cite

IntroductionMany people with Parkinson’s (PwP) are not given the opportunity or do not have adequate access to participate in clinical research. To address this, we have codeveloped with users an online platform that connects PwP to clinical studies in their local area. It enables site staff to communicate with potential participants and aims to increase the participation of the Parkinson’s community in research. This protocol outlines the mixed methods study protocol for the usability testing of the platform.Methods and analysisWe will seek user input to finalise the platform’s design, which will then be deployed in a limited launch for beta testing. The beta version will be used as a recruitment tool for up to three studies with multiple UK sites. Usability data will be collected from the three intended user groups: PwP, care partners acting on their behalf and site study coordinators. Usability questionnaires and website analytics will be used to capture user experience quantitatively, and a purposive sample of users will be invited to provide further feedback via semistructured interviews. Quantitative data will be analysed using descriptive statistics, and a thematic analysis undertaken for interview data. Data from this study will inform future platform iterations.Ethics and disseminationEthical approval was obtained from the University of Plymouth (3291; 3 May 2022). We will share our findings via a ‘Latest News’ section within the platform, presentations, conference meetings and national PwP networks.

show abstract

Parkinson's disease and Covid-19: The effect and use of telemedicine

Cited by 13 publications

References 57 publications

Mapping Factors That Affect the Uptake of Digital Therapeutics Within Health Systems: Scoping Review

Mapping Factors That Affect the Uptake of Digital Therapeutics Within Health Systems: Scoping Review

COVID-19 and neurological disorders: what might connect Parkinson’s disease to SARS-CoV-2 infection

Incorporating usability evaluation into iterative development of an online platform to support research participation in Parkinson’s disease: a mixed methods protocol

Contact Info

Product

Resources

About